Literature DB >> 11275413

Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia.

P Sánchez-Blázquez1, P Gómez-Serranillos, J Garzón.   

Abstract

The opioids heroin, methadone, buprenorphine, and morphine produce supraspinal antinociception in CD-1 mice that is antagonized by Cys(2), Tyr(3), Orn(5), Pen(7)-amide but not by naltrindole or nor-binaltorphimine. The patterns of GTP-binding regulatory proteins (G-proteins) activation exhibited by these agonists at mu-opioid receptors were characterized. The expression of alpha-subunits of Gi-protein classes, Gi1, Gi2, Gi3, Go1, Go2 and Gz, and those of the Gq-protein family, Gq and G11, was reduced by administration of antisense oligodeoxynucleotides (ODNs) complementary to sequences in their respective mRNAs. The ODN treatments demonstrated differences in the analgesic profiles of these opioids. Though the knock-down of G(i2)alpha or G(z)alpha subunits diminished the analgesic effects of the four opioids, impairment of G(i3)alpha did not modify the potency of morphine. In mice with reduced G(i1)alpha, G(o1)alpha or G(11)alpha levels, antinociception induced by heroin and methadone was diminished, but buprenorphine and morphine showed no change in their effects. Also, antinociception induced by heroin and buprenorphine, but neither morphine nor methadone, required intact G(o2)alpha or G(q)alpha levels. Thus, morphine, heroin, methadone, and buprenorphine showed different patterns of G-protein activation in evoking mu-opioid receptor-mediated supraspinal antinociception. Therefore, after binding identical receptors, each agonist determines the classes of GTP-binding regulatory transducer proteins to be activated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11275413     DOI: 10.1016/s0361-9230(00)00448-2

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  23 in total

1.  μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization.

Authors:  Jamie McPherson; Guadalupe Rivero; Myma Baptist; Javier Llorente; Suleiman Al-Sabah; Cornelius Krasel; William L Dewey; Chris P Bailey; Elizabeth M Rosethorne; Steven J Charlton; Graeme Henderson; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2010-07-20       Impact factor: 4.436

2.  Shared mechanisms for opioid tolerance and a transition to chronic pain.

Authors:  Elizabeth K Joseph; David B Reichling; Jon D Levine
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

3.  Differential activation of G-proteins by mu-opioid receptor agonists.

Authors:  Zuzana Saidak; Katherine Blake-Palmer; Debbie L Hay; John K Northup; Michelle Glass
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

4.  Agonist-dependent attenuation of mu-opioid receptor-mediated G-protein activation in the dorsal root ganglia of neuropathic rats.

Authors:  Ilona Obara; Ozge Gunduz Cinar; Katarzyna Starowicz; Sandor Benyhe; Anna Borsodi; Barbara Przewlocka
Journal:  J Neural Transm (Vienna)       Date:  2010-03-06       Impact factor: 3.575

Review 5.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

Review 6.  Effector antagonism by the regulators of G protein signalling (RGS) proteins causes desensitization of mu-opioid receptors in the CNS.

Authors:  Javier Garzón; María Rodríguez-Muñoz; Elena de la Torre-Madrid; Pilar Sánchez-Blázquez
Journal:  Psychopharmacology (Berl)       Date:  2005-04-14       Impact factor: 4.530

7.  μ-Opioid receptor coupling to Gα(o) plays an important role in opioid antinociception.

Authors:  Jennifer T Lamberts; Emily M Jutkiewicz; Richard M Mortensen; John R Traynor
Journal:  Neuropsychopharmacology       Date:  2011-06-08       Impact factor: 7.853

8.  Ligand-biased activation of extracellular signal-regulated kinase 1/2 leads to differences in opioid induced antinociception and tolerance.

Authors:  Erin N Bobeck; Susan L Ingram; Sam M Hermes; Sue A Aicher; Michael M Morgan
Journal:  Behav Brain Res       Date:  2015-10-20       Impact factor: 3.332

9.  Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine.

Authors:  Zhe Ding; Robert B Raffa
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

10.  Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine.

Authors:  Javier Garzón; Elena de la Torre-Madrid; María Rodríguez-Muñoz; Ana Vicente-Sánchez; Pilar Sánchez-Blázquez
Journal:  Mol Pain       Date:  2009-03-10       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.